10x Genomics Inc. (NASDAQ: TXG) open the trading on September 11, 2020, with great promise as it jumped 10.12% to $125.00. During the day, the stock rose to $125.30 and sunk to $112.00 before settling in for the price of $113.51 at the close. Taking a more long-term approach, TXG posted a 52-week range of $45.11-$115.90.
Nevertheless, stock’s Earnings Per Share (EPS) this year is 33.30%. This publicly-traded company’s shares outstanding now amounts to $98.98 million, simultaneously with a float of $61.40 million. The organization now has a market capitalization sitting at $11.39 billion. At the time of writing, stock’s 50-day Moving Average stood at $100.82, while the 200-day Moving Average is $82.48.
If we measure the efficiency of the company that is accounted for 713 employees. It has generated 421,050 per worker during the last fiscal year. Meanwhile, its income per employee was -53,512. The stock had 8.00 Receivables turnover and 0.67 Total Asset turnover. For the Profitability, stocks gross margin was +75.18, operating margin was -11.82 and Pretax Margin of -12.62.
10x Genomics Inc. (TXG) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Health Information Services industry. 10x Genomics Inc.’s current insider ownership accounts for 2.20%, in contrast to 85.90% institutional ownership. According to the most recent insider trade that took place on Sep 02, this organization’s See Remarks sold 6,058 shares at the rate of 112.14, making the entire transaction reach 679,365 in total value, affecting insider ownership by 67,500. Preceding that transaction, on Sep 02, Company’s Chief Commercial Officer sold 3,224 for 112.28, making the whole transaction’s value amount to 361,980. This particular insider is now the holder of 963 in total.
10x Genomics Inc. (TXG) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 6/29/2020 suggests? It has posted -$0.41 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$0.55) by $0.14. This company achieved a net margin of -12.71 while generating a return on equity of -31.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
10x Genomics Inc.’s EPS increase for this current 12-month fiscal period is 33.30% and is forecasted to reach -0.32 in the upcoming year.
10x Genomics Inc. (NASDAQ: TXG) Trading Performance Indicators
Let’s observe the current performance indicators for 10x Genomics Inc. (TXG). It’s Quick Ratio in the last reported quarter now stands at 3.50. The Stock has managed to achieve an average true range (ATR) of 5.42. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 45.33.
In the same vein, TXG’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.80, a figure that is expected to reach -0.31 in the next quarter, and analysts are predicting that it will be -0.32 at the market close of one year from today.
Technical Analysis of 10x Genomics Inc. (TXG)
[10x Genomics Inc., TXG] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 88.18% While, its Average True Range was 6.18.
Raw Stochastic average of 10x Genomics Inc. (TXG) in the period of the previous 100 days is set at 99.44%, which indicates a major rise in contrast to 98.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 52.67% that was higher than 41.66% volatility it exhibited in the past 100-days period.